Mechanistically, we have found that CML modification of the ECM contributes to improved fibroblast survival, which is partly attributable to an increased expression of anti-apoptotic proteins such as BCL2 and BCL-XL. Here, BCL2L1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.